University of Bayreuth

GLP-1 Drugs Alter Taste Perception, Enhancing Sweetness and Saltiness to Support Appetite Control

- About one in five patients taking GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro experience enhanced perception of sweetness and saltiness, which correlates with improved appetite control and satiety. - Participants who reported increased sweetness perception were twice as likely to experience enhanced satiety and 67% more likely to report reduced appetite compared to those with unchanged taste perception. - While taste changes don't directly correlate with BMI reduction, researchers suggest monitoring taste alterations could help clinicians assess treatment response and provide more personalized dietary guidance. - The study of 411 participants found significant weight loss across all three medications, with BMI reductions of 17.4% for Ozempic, 17.6% for Wegovy, and 15.5% for Mounjaro over treatment periods of 40-47 weeks.